(Q33413979)

English

A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

based on heuristic

1 reference

based on heuristic

monoclonal antibody

1 reference

based on heuristic

author name string

Amita Patnaik

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Patricia M LoRusso

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Wells A Messersmith

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Kyriakos P Papadopoulos

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Lia Gore

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Muralidhar Beeram

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Vanitha Ramakrishnan

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Amy H Kim

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Joseph C Beyer

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

L Mason Shih

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Walter C Darbonne

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Yan Xin

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Ron Yu

13

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Hong Xiang

14

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Rainer K Brachmann

15

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Colin D Weekes

16

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

17 March 2014

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

73

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

951-960

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

https://scigraph.springernature.com/pub.10.1007/s00280-014-2426-8

0 references

Connecting vascular and nervous system development: angiogenesis and the blood-brain barrier

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2426-8

21 January 2018

Neuropilin is a receptor for the axonal chemorepellent Semaphorin III

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2426-8

21 January 2018

Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2426-8

21 January 2018

Neuropilin-1 binds vascular endothelial growth factor 165, placenta growth factor-2, and heparin via its b1b2 domain

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2426-8

21 January 2018

Neuropilins in neoplasms: expression, regulation, and function.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2426-8

21 January 2018

Neuropilins: a new target for cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2426-8

21 January 2018

Function blocking antibodies to neuropilin-1 generated from a designed human synthetic antibody phage library

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2426-8

21 January 2018

Anti-neuropilin-1 (MNRP1685A): unexpected pharmacokinetic differences across species, from preclinical models to humans

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2426-8

21 January 2018

Pharmacokinetic and pharmacodynamic analysis of circulating biomarkers of anti-NRP1, a novel antiangiogenesis agent, in two phase I trials in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2426-8

21 January 2018

Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2426-8

21 January 2018

A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2426-8

21 January 2018

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2426-8

21 January 2018

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2426-8

21 January 2018

Clinical pharmacokinetics of bevacizumab in patients with solid tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2426-8

21 January 2018

Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2426-8

21 January 2018

Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2426-8

21 January 2018

A vascular niche and a VEGF–Nrp1 loop regulate the initiation and stemness of skin tumours

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2426-8

21 January 2018

Identifiers

10.1007/S00280-014-2426-8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33413979&oldid=1977293137"